Accessibility Menu
Johnson & Johnson logo

Johnson & Johnson

(NYSE) JNJ

Current Price$249.66
Market Cap$594.63BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1968)+134,969%
5 Year+69%
1 Year+63%
1 Month+5%
Johnson & Johnson last closing stock price
MetricPriceDate
Last closeUSD 247.022026-07-15
Johnson & Johnson stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.22%USD 263.402026-07-08
1 month+4.82%USD 235.662026-06-15
3 month+5.93%USD 233.202026-04-16
Year to date+20.69%USD 204.682025-12-31
1 year+63.17%USD 151.392025-07-15
3 year+68.65%USD 146.472023-07-14
5 year+69.14%USD 146.052021-07-16
Since inception+134,968.63%USD 0.181968-01-02

Johnson & Johnson Financials at a Glance

Market Cap

$594.63BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$97.93B

Net Income (TTM)

$21.04B

EPS (TTM)

$8.63

P/E Ratio

28.56

Dividend

$5.24

Beta (Volatility)

0.18 (Low)

Price

$249.66

Volume

450,762

Open

$248.90

Previous Close

$249.66

Daily Range

$246.34 - $253.51

52-Week Range

$162.30 - $269.43

Estimated Earnings Date

Oct 13, 2026

JNJ News

TMF-Pills-Blue-StockVStock.png

Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026?

Brendan CoffeyJul 16, 2026
JNJ

Is Johnson & Johnson a Buy After Its Latest Earnings Report?

Eric VolkmanJul 15, 2026
Two people looking at a chart.

5 Best High Dividend Mutual Funds to Buy in 2026

Matt DiLalloJul 14, 2026
dividend-stock-cash

This Dividend King Has Raised Its Payout for More Than 60 Straight Years. But Is the Stock Still a Buy?

Daniel SparksJul 14, 2026
GettyImages-two people smile and look at computer

Billionaire Ken Griffin Boosted His Stake in This Dividend King by 146%. Here's Why It's a Dream Stock for Risk-Averse Investors.

Adria CiminoJul 12, 2026
GettyImages-941740978-1201x801-d21b45d

The Largest Healthcare Companies by Market Cap in July 2026

Lyle DalyJul 7, 2026
Coins money growth

5 Dividend Kings Long-Term Investors Should Own for the Next 20 Years

Justin PopeJul 7, 2026
Axesome

3 Stocks to Buy and Hold: The Long-Term Play for Your Portfolio

James HalleyJul 6, 2026
Page 1

JNJ: Motley Fool Moneyball Superscore

74

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Johnson & Johnson

Johnson & Johnson makes medicines and medical devices for hospitals and patients. Its products help treat diseases like cancer and support surgeries and vision care. The company’s work supports doctors, hospitals, and people needing advanced healthcare solutions.

What’s in the J&J Toolbox?

  • Innovative Medicine (64.2% of 2024 sales): Prescription drugs for cancer, immune disorders, and infectious diseases, used by hospitals and specialists.
  • MedTech (35.8% of 2024 sales): Medical devices for surgery, orthopaedics (joint replacements), and cardiovascular care, serving hospitals and clinics.
  • Vision Care: Disposable contact lenses (ACUVUE) and intraocular lenses for eye surgeries, used by eye doctors and patients.
  • Advanced Surgery: Tools and products for wound closure and minimally invasive procedures, supporting surgeons and operating rooms.
  • Neurovascular and Heart Recovery: Devices for stroke treatment and heart support, used in emergency and critical care settings.

Growth Moves: J&J’s Expansion Playbook

  • Spun off Consumer Health as Kenvue in 2023 to focus on higher-growth segments.
  • Acquired Shockwave Medical in 2024 to expand cardiovascular device offerings.
  • Bought Ambrx Biopharma and Proteologix in 2024 to strengthen drug development pipeline.
  • Purchased V-Wave in 2024, adding heart failure treatment technology.
  • Expanded global manufacturing to 64 sites, supporting worldwide distribution and local market access.

Why J&J Stays in the Game

Johnson & Johnson operates in nearly every country, supplying hospitals and clinics worldwide. Its large research budget supports new drug and device development. The company’s broad product range and global reach help manage risks from market changes.

Five Things You Need to Know

  • Revenue was $88.8 billion in 2024, up 4.3% from 2023.
  • Innovative Medicine led with $57.0 billion in 2024, 64.2% of sales.
  • MedTech sales reached $31.9 billion in 2024, up 4.8% year-on-year.
  • R&D spending was $17.2 billion in 2024, 19.4% of sales.

Bottom Line

Johnson & Johnson has shifted to focus on prescription drugs and medical devices. Its size, research investment, and global presence support steady adaptation in healthcare markets.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

140,800

CEO

Joaquin Duato, MBA

Website

www.jnj.com

Headquarters

New Brunswick, NJ 08933, US

JNJ Financials

Key Financial Metrics (TTM)

Gross Margin

69.12%

Operating Margin

26.87%

Net Income Margin

21.83%

Return on Equity

26.26%

Return on Capital

19.77%

Return on Assets

10.47%

Earnings Yield

3.50%

Dividend Yield

2.12%

Payout Ratio

59.52%

Stock Overview

Market Cap

$594.63BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.41B

Volume

450.76K

Avg. Volume

8.18M

Financials (TTM)

Gross Profit

$68.99B

Operating Income

$26.26B

EBITDA

$31.92B

Operating Cash Flow

$22.87B

Capital Expenditure

-$5.07B

Free Cash Flow

$17.80B

Cash & ST Invst.

$22.05B

Total Debt

$54.99B

Johnson & Johnson Performance Analysis

Johnson & Johnson annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 80,062,000,000-14.6%
20232023-12-31USD 85,152,000,0006.4%
20242024-12-31USD 88,819,000,0004.3%
20252025-12-31USD 94,178,000,0006.0%
Johnson & Johnson sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-281.1%
Q42025-12-282.4%
Q12026-03-29-2.0%
Q22026-06-305.2%
Johnson & Johnson annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 6.73-13.7%
20232023-12-31USD 5.53-17.8%
20242024-12-31USD 5.794.6%
20252025-12-31USD 11.0390.6%
Johnson & Johnson sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-28-7.4%
Q42025-12-28-0.9%
Q12026-03-291.9%
Q22026-06-306.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$25.31B

+6.6%

Gross Profit

$18.50B

+14.8%

Gross Margin

73.11%

N/A

Market Cap

$594.63BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.20M

N/A

Employees

141,700

N/A

Net Income

$5.53B

-0.1%

EBITDA

$7.17B

-17.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$22.05B

-43.1%

Total Debt

$54.99B

+5.2%

Accounts Receivable

$17.72B

+10.6%

Inventory

$14.58B

+15.2%

Long Term Debt

$37.53B

-2.2%

Short Term Debt

$17.46B

+25.6%

Return on Assets

10.47%

N/A

Return on Invested Capital

18.08%

N/A

Free Cash Flow

$1.47B

-56.6%

Operating Cash Flow

$2.51B

-39.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ABBVAbbVie Inc.
$254.45+4.24%
UNHUnitedHealth Group Incorporated
$423.38+1.16%
MRKMerck & Co., Inc.
$127.68+3.29%
NVSNovartis AG
$152.73+1.28%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$15.60-0.00%
ATAIAtaiBeckley
$7.15+0.33%
NOKNokia
$10.38-0.08%
ONDSOndas
$6.65-0.06%

Questions About JNJ

What is the current price of Johnson & Johnson?

Johnson & Johnson is trading at $249.66 per share.

What is the 52-week range for Johnson & Johnson?

Over the past 52 weeks, Johnson & Johnson has traded between $162.30 and $269.43.

How much debt does Johnson & Johnson have?

As of the most recent reporting period, Johnson & Johnson reported total debt of $54.99B.

How much cash does Johnson & Johnson have on hand?

Johnson & Johnson reported $21.69B in cash and cash equivalents in its most recent financial results.

What is Johnson & Johnson’s dividend yield?

Johnson & Johnson currently has a dividend yield of 2.12%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services